Hyperthermic Antiblastic Perfusion in the Treatment of Loco-Regional Spreading Limb Melanoma

Franco Di Filippo, R. Garinei, D. Giannarelli, M. Anzà, F. Cavaliere, C. Botti, P. Perri, S. Di Filippo, A. Psaila, A. Callopoli, R. Maialetti, F. Sega, F. Frezza, C. Viticci

Research output: Contribution to journalArticlepeer-review


On the basis of personal experience and a review of the literature, the authors have evaluated the results obtained with hyperthermic antiblastic perfusion (HAP) for the treatment of stage II, III and IIIAB limb melanoma. The evaluation showed that today HAP may be considered a safe and effective treatment, with a major complication rate ranging between 1% and 4%. In terms of tumor response, locoregional control and survival, this treatment has provided better results than other regional chemotherapeutic modalities and undoubtedly better results than those obtained with conventional, even radical, surgery. The multivariate analysis showed that, of the treatment-related prognostic factors, the minimum tumor temperature influenced the percentage of complete response (CR) to the greatest extent (P

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalJournal of Experimental and Clinical Cancer Research
Issue number4 SUPPL.
Publication statusPublished - Dec 2003


  • Hyperthermic antiblastic perfusion
  • Limb melanoma
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Hyperthermic Antiblastic Perfusion in the Treatment of Loco-Regional Spreading Limb Melanoma'. Together they form a unique fingerprint.

Cite this